Literature DB >> 19861540

Tumor growth instability and its implications for chemotherapy.

Paolo Castorina1, Daniela Carcò, Caterina Guiot, Thomas S Deisboeck.   

Abstract

Optimal delivery of chemotherapy intensity is dependent on host- and tumor-specific characteristics. In this article, the chemotherapy late intensity schedule is revised to account for tumor growth instability, where a small tumor cell fraction emerges that exhibits a higher proliferation rate than the parent strain. Modeling this instability as simplified two-population dynamics, we find that: (a) if this instability precedes the onset of treatment, the slope of the linear increase of the drug concentration for the standard "Norton-Simon late intensity schedule" changes and the initial value of the dose strongly depends on the ratio of the two tumor cell populations and on their distinct growth rates; and (b) if the instability trails the initial treatment, the effective chemotherapeutic drug concentration changes as well. Both cases point toward testable potential refinements of the Norton-Simon late intensity schedule.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19861540      PMCID: PMC2783798          DOI: 10.1158/0008-5472.CAN-09-0653

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy.

Authors:  Larry Norton
Journal:  Oncologist       Date:  2005 Jun-Jul

2.  The Norton-Simon hypothesis revisited.

Authors:  L Norton; R Simon
Journal:  Cancer Treat Rep       Date:  1986-01

3.  Laboratory models: some historical perspective.

Authors:  H E Skipper
Journal:  Cancer Treat Rep       Date:  1986-01

4.  Is Gompertzian or exponential kinetics a valid description of individual human cancer growth?

Authors:  M W Retsky; D E Swartzendruber; R H Wardwell; P D Bame
Journal:  Med Hypotheses       Date:  1990-10       Impact factor: 1.538

5.  Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

Authors:  M Colleoni; G Viale; D Zahrieh; L Bottiglieri; R D Gelber; P Veronesi; A Balduzzi; R Torrisi; A Luini; M Intra; S Dellapasqua; A Cardillo; R Ghisini; G Peruzzotti; A Goldhirsch
Journal:  Ann Oncol       Date:  2007-11-06       Impact factor: 32.976

6.  Does tumor growth follow a "universal law"?

Authors:  Caterina Guiot; Piero Giorgio Degiorgis; Pier Paolo Delsanto; Pietro Gabriele; Thomas S Deisboeck
Journal:  J Theor Biol       Date:  2003-11-21       Impact factor: 2.691

7.  Application of theoretical models to chemotherapy protocol design.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1986-01

8.  Quantitative model for multiple levels of drug resistance in clinical tumors.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1983-10

9.  Modelling chemotherapy resistance in palliation and failed cure.

Authors:  Helen C Monro; Eamonn A Gaffney
Journal:  J Theor Biol       Date:  2008-12-11       Impact factor: 2.691

10.  Dose-dense adjuvant chemotherapy for primary breast cancer.

Authors:  Monica Fornier; Larry Norton
Journal:  Breast Cancer Res       Date:  2005-02-10       Impact factor: 6.466

View more
  10 in total

Review 1.  The dynamics of drug resistance: a mathematical perspective.

Authors:  Orit Lavi; Michael M Gottesman; Doron Levy
Journal:  Drug Resist Updat       Date:  2012-03-03       Impact factor: 18.500

2.  Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy.

Authors:  Markus R Owen; I Johanna Stamper; Munitta Muthana; Giles W Richardson; Jon Dobson; Claire E Lewis; Helen M Byrne
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

3.  Nutrient supply, cell spatial correlation and Gompertzian tumor growth.

Authors:  P Castorina; D Carco'
Journal:  Theory Biosci       Date:  2021-05-14       Impact factor: 1.919

4.  Exploiting clinical trial data drastically narrows the window of possible solutions to the problem of clinical adaptation of a multiscale cancer model.

Authors:  Georgios S Stamatakos; Eleni C Georgiadi; Norbert Graf; Eleni A Kolokotroni; Dimitra D Dionysiou
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

5.  A quantitative theory of solid tumor growth, metabolic rate and vascularization.

Authors:  Alexander B Herman; Van M Savage; Geoffrey B West
Journal:  PLoS One       Date:  2011-09-29       Impact factor: 3.240

6.  How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient.

Authors:  Elsa Hansen; Robert J Woods; Andrew F Read
Journal:  PLoS Biol       Date:  2017-02-09       Impact factor: 8.029

7.  Three-dimensional tumor growth in time-varying chemical fields: a modeling framework and theoretical study.

Authors:  Markos Antonopoulos; Dimitra Dionysiou; Georgios Stamatakos; Nikolaos Uzunoglu
Journal:  BMC Bioinformatics       Date:  2019-08-27       Impact factor: 3.169

8.  Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations.

Authors:  Niraj Kumar; Gwendolyn M Cramer; Seyed Alireza Zamani Dahaj; Bala Sundaram; Jonathan P Celli; Rahul V Kulkarni
Journal:  Sci Rep       Date:  2019-07-26       Impact factor: 4.379

9.  Dealing with diversity in computational cancer modeling.

Authors:  David Johnson; Steve McKeever; Georgios Stamatakos; Dimitra Dionysiou; Norbert Graf; Vangelis Sakkalis; Konstantinos Marias; Zhihui Wang; Thomas S Deisboeck
Journal:  Cancer Inform       Date:  2013-05-07

10.  Constructal approach to cell membranes transport: Amending the 'Norton-Simon' hypothesis for cancer treatment.

Authors:  Umberto Lucia; Antonio Ponzetto; Thomas S Deisboeck
Journal:  Sci Rep       Date:  2016-01-29       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.